Floatz logo

Bortezomib

Complex Karyotype

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Complex Karyotype cohort.

Asset / SponsorPhaseRating
Evomela
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Decitabine
Nanfang Hospital, Southern Medical University
Phase 2CCC
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2CCC
DEXAMETHASONE
Institute of Hematology & Blood Diseases Hospital, China
N/AD

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →